Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Dioscorea Extract
Therapeutic Area : Neurology
Study Phase : Phase II
Recipient : NeuroBo Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Merger
Details : NeuroBo will focus on advancing the company’s clinical-stage pipeline for neurodegenerative diseases.
Product Name : Undisclosed
Product Type : Plant Extract/Herbal
Upfront Cash : Undisclosed
January 10, 2020
Lead Product(s) : Dioscorea Extract
Therapeutic Area : Neurology
Highest Development Status : Phase II
Recipient : NeuroBo Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Merger
Lead Product(s) : Gemcabene
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase II
Recipient : Gabrail Cancer Center Research
Deal Size : Inapplicable
Deal Type : Inapplicable
Gemcabene for the Treatment of Pediatric NAFLD
Details : Gemcabene is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Non-alcoholic Fatty Liver Disease.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 19, 2018
Lead Product(s) : Gemcabene
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II
Recipient : Gabrail Cancer Center Research
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
